Interleukin-12

• 

  Subject Areas on Research

  • A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. 
  • A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas. 
  • A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. 
  • A promoter polymorphism in the gene encoding interleukin-12 p40 (IL12B) is associated with mortality from cerebral malaria and with reduced nitric oxide production. 
  • A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. 
  • Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. 
  • An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. 
  • Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. 
  • Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha. 
  • CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. 
  • CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. 
  • Characterization of a recombinant adenovirus vector encoding heat-inducible feline interleukin-12 for use in hyperthermia-induced gene-therapy. 
  • Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. 
  • Coadministration of IL-12 or IL-10 expression cassettes drives immune responses toward a Th1 phenotype. 
  • Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models. 
  • Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. 
  • Comparative ability of plasmid IL-12 and IL-15 to enhance cellular and humoral immune responses elicited by a SIVgag plasmid DNA vaccine and alter disease progression following SHIV(89.6P) challenge in rhesus macaques. 
  • Costimulator dependence of lymphokine secretion by naive and activated CD4+ T lymphocytes from TCR transgenic mice. 
  • Cyclic AMP modulates the functional plasticity of immature dendritic cells by inhibiting Src-like kinases through protein kinase A-mediated signaling. 
  • Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. 
  • Cytokine transcriptional events during helper T cell subset differentiation. 
  • Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. 
  • Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis. 
  • DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA. 
  • DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers. 
  • DNA-MVA vaccine protection after X4 SHIV challenge in macaques correlates with day-of-challenge antiviral CD4+ cell-mediated immunity levels and postchallenge preservation of CD4+ T cell memory. 
  • Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma. 
  • Deletion of a conserved cis-element in the Ifng locus highlights the role of acute histone acetylation in modulating inducible gene transcription. 
  • Depressed interleukin-12-producing activity by monocytes correlates with adverse clinical course and a shift toward Th2-type lymphocyte pattern in severely injured male trauma patients. 
  • Diacylglycerol kinase zeta regulates microbial recognition and host resistance to Toxoplasma gondii. 
  • Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. 
  • Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection. 
  • Down-regulation of IL-2 receptor alpha (CD25) characterizes human gammadelta-T cells rendered resistant to apoptosis after CD2 engagement in the presence of IL-12. 
  • Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. 
  • Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. 
  • Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. 
  • Enhancement of radiotherapy by hyperthermia-regulated gene therapy. 
  • Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. 
  • Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation. 
  • Expression of cytokine mRNA in murine splenic dendritic cells and better induction of T cell-derived cytokines by dendritic cells than by macrophages during in vitro costimulation assay using specific antigens. 
  • GPI-defective monocytes from paroxysmal nocturnal hemoglobinuria patients show impaired in vitro dendritic cell differentiation. 
  • Gastroesophageal reflux-associated aspiration alters the immune response in asthma. 
  • Heat-induced gene expression as a novel targeted cancer gene therapy strategy. 
  • Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. 
  • Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection. 
  • Host response to infection: the role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages. 
  • Human gammadelta-T cells in adoptive immunotherapy of malignant and infectious diseases. 
  • IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. 
  • IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. 
  • IL-12/GM-CSF coadministration in an SIV DNA prime/protein boost protocol enhances Gag-specific T cells but not virus-specific neutralizing antibodies in rhesus macaques. 
  • Immune responses to DNA in normal and aberrant immunity. 
  • Immune therapies for neuroblastoma. 
  • Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. 
  • Immunostimulatory properties of genomic DNA from different bacterial species. 
  • Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. 
  • Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. 
  • In-vivo impaired T helper 1 cell development in submandibular lymph nodes due to IL-12 deficiency following antigen injection into the anterior chamber of the eye. 
  • Induction of IL-12 and chemokines by hyaluronan requires adhesion-dependent priming of resident but not elicited macrophages. 
  • Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. 
  • Induction of immune activation by a novel immunomodulatory oligonucleotide without thymocyte apoptosis. 
  • Induction of the human heat shock promoter HSP70B by nutritional stress: implications for cancer gene therapy. 
  • Influence of backbone chemistry on immune activation by synthetic oligonucleotides. 
  • Inhibition of interferon gamma induced interleukin 12 production: a potential mechanism for the anti-inflammatory activities of tumor necrosis factor. 
  • Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. 
  • Inhibition of murine macrophage IL-12 production by natural and synthetic DNA. 
  • Interleukin 12 at the site of disease in tuberculosis. 
  • Interleukin-15 augments superoxide production and microbicidal activity of human monocytes against Candida albicans. 
  • Intraperitoneal fluid neopterin, nitrate, and tryptophan after regional administration of interleukin-12. 
  • LAB/NTAL facilitates fungal/PAMP-induced IL-12 and IFN-γ production by repressing β-catenin activation in dendritic cells. 
  • Lack of the receptor for advanced glycation end-products attenuates E. coli pneumonia in mice. 
  • Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. 
  • Long-term control of simian immunodeficiency virus mac251 viremia to undetectable levels in half of infected female rhesus macaques nasally vaccinated with simian immunodeficiency virus DNA/recombinant modified vaccinia virus Ankara. 
  • Low interleukin-12 activity in severe Plasmodium falciparum malaria. 
  • Lower concentrations of methyl-β-cyclodextrin combined with interleukin-2 can preferentially induce activation and proliferation of natural killer cells in human peripheral blood. 
  • Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo. 
  • Modular utilization of distal cis-regulatory elements controls Ifng gene expression in T cells activated by distinct stimuli. 
  • Modulation of interleukin-12 mRNA expression in leukocytes of cancer patients treated with CM101. 
  • Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model. 
  • Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. 
  • Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. 
  • Non-erythroid effects of erythropoietin. 
  • Oral administration of IL-12 suppresses anaphylactic reactions in a murine model of peanut hypersensitivity. 
  • Paired Toll-like receptor agonists enhance vaccine therapy through induction of interleukin-12. 
  • Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. 
  • Peripheral blood dendritic cells, but not monocyte-derived dendritic cells, can augment human NK cell function. 
  • Pharmacokinetics of combined gene therapy expressing constitutive human GM-CSF and hyperthermia-regulated human IL-12. 
  • Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. 
  • Plasma interleukin-12 in malaria-tolerant papua new guineans: inverse correlation with Plasmodium falciparum parasitemia and peripheral blood mononuclear cell nitric oxide synthase activity. 
  • Platelets deliver costimulatory signals to antigen-presenting cells: a potential bridge between injury and immune activation. 
  • Plexin-B2 and Plexin-D1 in dendritic cells: expression and IL-12/IL-23p40 production. 
  • Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. 
  • Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL-12/GM-CSF co-administration. 
  • Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. 
  • Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. 
  • Reduced interleukin-12 and transforming growth factor-beta1 in severe childhood malaria: relationship of cytokine balance with disease severity. 
  • Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. 
  • Resistance of CD7-deficient mice to lipopolysaccharide-induced shock syndromes. 
  • Retrovirus-elicited interleukin-12 and tumour necrosis factor-alpha as inducers of interferon-gamma-mediated pathology in mouse AIDS. 
  • Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. 
  • Role of interleukin 12 and costimulators in T cell anergy in vivo. 
  • Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. 
  • Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. 
  • Serum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controls. 
  • Stability of Th1 and Th2 populations. 
  • Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. 
  • Systemic cytokine immunotherapy for experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency. 
  • Systemic dissemination of viral vectors during intratumoral injection. 
  • Systemic vector leakage and transgene expression by intratumorally injected recombinant adenovirus vectors. 
  • The immunocytokine NHS-IL12 as a potential cancer therapeutic. 
  • The influence of DNA sequence on the immunostimulatory properties of plasmid DNA vectors. 
  • The influence of lipofectin on the in vitro stimulation of murine spleen cells by bacterial DNA and plasmid DNA vectors. 
  • The role for interleukin-12 therapy of cutaneous T cell lymphoma. 
  • The role of IL12 in helper T-cell differentiation. 
  • The role of the macrophage scavenger receptor in immune stimulation by bacterial DNA and synthetic oligonucleotides. 
  • Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. 
  • Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. 
  • Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. 
  • Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice. 
  • Visualization of IL-12/23p40 in vivo reveals immunostimulatory dendritic cell migrants that promote Th1 differentiation. 
  • [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. 
  • [Study of immunoregulation of dendritic cells in allergic rhinitis]. 
• 

  Keywords of People

  • Lee, Walter T, Associate Professor of Surgery, Radiation Oncology
  • Zhong, Xiaoping, Professor of Pediatrics, Immunology